Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: Lack of potency and selection of resistance mutations

Journal of Viral Hepatitis

Volumn 21, Issue 11, 2014, Pages 809-817

  Ayres, A ^a   Yuen, L ^a   Jackson, K M ^a   Manoharan, S ^b   Glass, A ^b   Maley, M ^b   Yoo, W ^c   Hong, S P ^c   Kim, S O ^c   Luciani, F ^d   Bowden, D S ^a   Bayliss, J ^a   Levy, M T ^b   Locarnini, S A ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

^c Genematrix Inc   (South Korea)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

hepatitis B virus; lamivudine in pregnancy; primary drug resistance; ultra deep pyrosequencing

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENTROPY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LINKAGE ANALYSIS; MICROBIAL DIVERSITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY; PREGNANT WOMAN; PROSPECTIVE STUDY; PYROSEQUENCING; REVERSE TRANSCRIPTASE AMINO ACID SUBSTITUTION; SHANNON ENTROPY; SHORT COURSE THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; TREATMENT RESPONSE; ULTRA DEEP PYROSEQUENCING; VIREMIA; VIRUS LOAD; VIRUS TRANSMISSION; BLOOD; DRUG EFFECTS; GENETIC SELECTION; GENETIC VARIABILITY; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MUTATION; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIROLOGY;

ANTIVIRAL AGENTS; BLOOD; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HEPATITIS B; HEPATITIS B VIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; SELECTION, GENETIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84908023727     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12212     Document Type: Article

References (29)

1. Chen DS,. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50 (4): 805-816.
2. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL,. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepatitis 2003; 10 (4): 294-297.
3. Gambarin-Gelwan M,. Hepatitis B in pregnancy. Clin Liver Dis 2007; 11 (4): 945-963.
4. Wiseman E, Fraser MA, Holden S, et al,. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190 (9): 489-492.
5. Xu WM, Cui YT, Wang L, et al,. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepatitis 2009; 16 (2): 94-103.
6. Petersen J,. HBV treatment and pregnancy. J Hepatol 2011; 55 (6): 1171-1173.
7. Han GR, Cao MK, Zhao W, et al,. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55 (6): 1215-1221.
8. Pan CQ, Mi LJ, Bunchorntavakul C, et al,. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012; 57 (9): 2423-2429.
9. Zoulim F, Locarnini S,. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137 (5): 1593-608.e1-1593-608.e2.
10. Niesters HG, Zoulim F, Pichoud C, et al,. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother 2010; 54 (3): 1283-1289.
11. Han KH, Hong SP, Choi SH, et al,. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther 2011; 16 (1): 77-87.
12. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR,. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 2009; 83 (4): 1718-1726.
13. Margeridon-Thermet S, Shulman NS, Ahmed A, et al,. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199 (9): 1275-1285.
14. Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, et al,. Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment. Antimicrob Agents Chemother 2013; 57 (1): 343-349.
15. Li H, Durbin R,. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26 (5): 589-595.
16. Gerstung M, Beisel C, Rechsteiner M, et al,. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun 2012; 3: 811.
17. Bland JM, Altman DG,. Multiple significance tests: the Bonferroni method. BMJ 1995; 310 (6973): 170.
18. Zagordi O, Bhattacharya A, Eriksson N, Beerenwinkel N,. ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data. BMC Bioinformatics 2011; 12: 119.
19. McElroy K, Zagordi O, Bull R, Luciani F, Beerenwinkel N,. Accurate single nucleotide variant detection in viral populations by combining probabilistic clustering with a statistical test of strand bias. BMC Genomics 2013; 14 (1): 501.
20. Bull RA, Luciani F, McElroy K, et al,. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog 2011; 7 (9): e1002243.
21. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: The R Foundation for Statistical Computing, 2011.
22. Ono-Nita SK, Kato N, Shiratori Y, et al,. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999; 29 (3): 939-945.
23. Gunther S, Fischer L, Pult I, Sterneck M, Will H,. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 25-137.
24. van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW,. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000; 32 (6): 1040-1041.
25. Warner N, Locarnini S,. The antiviral drug selected hepatitis B virus rtA181T/sW172∗ mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48 (1): 88-98.
26. Chisari FV, Ferrari C,. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
27. Lin CL, Tsai SL, Lee TH, Chien RN, Liao SK, Liaw YF,. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 2005; 54 (1): 152-161.
28. Chen L, Zhang Q, Yu DM, Wan MB, Zhang XX,. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J Hepatol 2009; 50 (5): 895-905.
29. Pan CQ, Duan ZP, Bhamidimarri KR, et al,. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10 (5): 452-459.